中国药物警戒 ›› 2020, Vol. 17 ›› Issue (9): 553-558.
DOI: 10.19803/j.1672-8629.2020.09.02

• 基础与临床研究 • 上一篇    下一篇

利用人诱导多能干细胞分化的心肌细胞评价莫西沙星和左氧氟沙星与抗心律失常药物联用的心脏毒性风险

汪祺1, 颜玉静1, 任璐1, 文海若1,*, 郭建2,*   

  1. 1中国食品药品检定研究院,北京 100050;
    2首都医科大学附属北京同仁医院急诊科,北京 100730
  • 收稿日期:2020-08-17 修回日期:2020-08-17 出版日期:2020-09-15 发布日期:2020-08-17
  • 通讯作者: *文海若,女,博士,研究员,药理毒理。E-mail:wenhairuo@nifdc.org.cn;郭建,男,硕士,主治医师,临床药理。E-mail:guojian2221@163.com
  • 作者简介:汪祺,女,博士,副研究员,毒理。
  • 基金资助:
    国家自然科学基金项目(81503068,81503347);国家十三五“重大新药创制”(2018ZX09201017)

Cardiotoxicity Evaluation of Moxifloxacin and Levofloxacin Used in Conjunction with Antiarrhythmic Drugs through HiPSC-CM

WANG Qi1, YAN Yujing1, REN Lu1, WEN Hairuo1,*, GUO Jian2,*   

  1. 1National Institutes for Food and Drug Control, Beijing 100050, China;
    2Emergency Department, Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, 100730, China
  • Received:2020-08-17 Revised:2020-08-17 Online:2020-09-15 Published:2020-08-17

PDF (PC)

184

摘要： 目的 利用人诱导多能干细胞分化的心肌细胞和实时细胞分析系统评价喹诺酮类抗生素莫西沙星和左氧氟沙星与抗心律失常药物奎尼丁、普鲁卡因胺和胺碘酮联用的心脏毒性风险。方法 人诱导多能干细胞分化的心肌细胞接种于实时细胞分析系统 Cardio E-Plate 96孔板并给予不同浓度的莫西沙星、左氧氟沙星、奎尼丁、普鲁卡因胺和胺碘酮,根据人诱导多能干细胞分化的心肌细胞的标准化细胞指数及标准化搏动频率筛选毒性浓度。以莫西沙星和左氧氟沙星最高无毒性浓度和最低有毒性浓度预处理24 h后,分别给予不同浓度的奎尼丁、普鲁卡因胺和胺碘酮,比较各组间标准化细胞指数的差异。结果 莫西沙星、左氧氟沙星、奎尼丁、普鲁卡因胺和胺碘酮均可诱导标准化细胞指数降低(P<0.05)。莫西沙星与奎尼丁或普鲁卡因胺联合给药后可导致标准化细胞指数降低(P<0.05);左氧氟沙星与胺碘酮联合给药后可导致标准化细胞指数降低(P<0.05)。结论 莫西沙星和左氧氟沙星与抗心律失常药物联用后可增加心脏毒性风险,基于人诱导多能干细胞分化的心肌细胞和实时细胞分析系统的体外评价模型在药物心脏毒性预测上具有应用前景。

关键词: 莫西沙星, 左氧氟沙星, 心律失常, 人诱导多能干细胞, 心肌细胞, 实时细胞分析, 心脏毒性, 奎尼丁, 普鲁卡因胺, 胺碘酮

Abstract: Objective To evaluate the cardiotoxicity of quinolone antibiotics used in combination with antiarrhythmic drugs using human induced pluripotent stem cell derived cardiac myocytes (hiPSC-CM) and the real-time cell analyzer (RTCA). Methods The hiPSC-CM was seeded onto the RTCA Cardio E-Plate 96 and treated with moxifloxacin, levofloxacin, quinidine, procainamide, and amiodarone of different concentrations, while the normalized cell index (NCI) and normalized beat rate (NBR) were used for the screening of toxic concentrations. After 24 hours of pretreatment with the highest non-toxic concentration and the lowest toxic concentration of moxifloxacin or levofloxacin, different concentrations of quinidine, procainamide, and amiodarone were used to treat the cells, and the difference in the NCI between the groups was compared. Results Moxifloxacin, levofloxacin, quinidine, procainamide, and amiodarone all decreased the NCI when used alone to treat the cells (P <0.05). Moxifloxacin combined with quinidine or procainamide reduced the NCI of cells (P <0.05), so did levofloxacin combined with amiodarone (P <0.05). Conclusion This study suggests that the combination of moxifloxacin and levofloxacin with antiarrhythmic drugs could increase the risk of cardiotoxicity, and that the in vitro evaluation model based on hiPSC-CM and RTCA is applicable to the prediction of risks of drug cardiotoxicity.

Key words: moxifloxacin, levofloxacin, arrhythmia, human induced pluripotent stem cell, cardiac myocytes, cardial, real-time cell analysis, cardiotoxicity, quinidine, procainamidel, amiodarone

中图分类号: